TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05355753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFT8634
Description: Oral dose of CFT8634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFT8634
Description: Oral dose of CFT8634
Study: NCT04034615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchyme Stem Cells high-dose group
Description: Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
Study: NCT05883878

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PRS
Description: genetic test for the evaluation of PRS cardiovascular risk

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PRS
Description: genetic test for the evaluation of PRS cardiovascular risk

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital app and wearable device
Description: a wearable device connected with its app

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital app and wearable device
Description: a wearable device connected with its app
Study: NCT06123156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildénafil during 10 months (50mg daily), start 30 days after surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 platelet during 10 months (daily), start 30 days after surgery
Study: NCT05422521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples and 18FDG PET-CT exams
Description: * 18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month)~* blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)
Study: NCT06544941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Bassinet
Description: The SNOO will respond to a crying or fussing infant in order to soothe and calm it down.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO
Description: The HALO is a commercially available bassinet
Study: NCT06623643

Intervention type: DIAGNOSTIC_TEST
Intervention: The investigation of melatonin and cortisol levels in the saliva
Description: In the related study, patient data from individuals who visited the Oral and Maxillofacial Radiology clinic at Van Yüzüncü Yıl University Faculty of Dentistry with complaints of bruxism will be used. The diagnosis of bruxism will be made based on clinical data. Diagnoses will be made by Dr. Sema KAYA using clinical findings such as patient history used for the current diagnosis of bruxism, tooth wear, tooth mobility, pain in the temporomandibular joint (TMJ), headaches, pain in the chewing muscles, hypertrophy, and a feeling of fatigue. Before taking the saliva samples, patients will be asked to rinse their mouths with sterile water, and then they will be asked to spit into sterile plastic containers. After approximately 3 mL of saliva is collected, it will be transferred to appropriate Eppendorf tubes and stored at -80°C. Melatonin and cortisol levels will later be analyzed using the enzyme-linked immunosorbent assay (ELISA) method.

Intervention type: DIAGNOSTIC_TEST
Intervention: The investigation of melatonin and cortisol levels in the saliva
Description: In the related study, patient data from individuals who visited the Oral and Maxillofacial Radiology clinic at Van Yüzüncü Yıl University Faculty of Dentistry with complaints of bruxism will be used. The diagnosis of bruxism will be made based on clinical data. Diagnoses will be made by Dr. Sema KAYA using clinical findings such as patient history used for the current diagnosis of bruxism, tooth wear, tooth mobility, pain in the temporomandibular joint (TMJ), headaches, pain in the chewing muscles, hypertrophy, and a feeling of fatigue. Before taking the saliva samples, patients will be asked to rinse their mouths with sterile water, and then they will be asked to spit into sterile plastic containers. After approximately 3 mL of saliva is collected, it will be transferred to appropriate Eppendorf tubes and stored at -80°C. Melatonin and cortisol levels will later be analyzed using the enzyme-linked immunosorbent assay (ELISA) method.
Study: NCT05439057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is infused at a rate of 0.3 mg/kg/hr from induction of anesthesia until 20 minutes before the end of operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Normal saline is infused at a rate of 0.3 ml/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
Study: NCT06220097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells
Description: Bridging therapies from enrollment before CD19 CAR-T infusion. A treatment regimen containing mitoxantrone hydrochloride liposome injection, including but not limited to the following recommended regimens: R-MINE regimen (rituximab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) G-MINE regimen (obinutuzumab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) MAE regimen (mitoxantrone liposome hydrochloride + cytarabine + etoposide) . The recommended dose of mitoxantrone liposome hydrochloride is not limited. For patients who achieve SD or better after one cycle of bridging treatment, it is up to the investigator to decide whether to receive CAR-T therapy. Fludarabine-based lymphodepletion chemotherapy was followed by CD19 CAR-T cells (relma-cel, axi-cel or humanized CAR19). Relma-cel and axi-cel will be infused according to the instructions. CART19 infusion is conducted at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
Study: NCT05378360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DWP708
Description: Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DWP708
Description: Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DWP708
Description: Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DWP708
Description: Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days
Study: NCT06135857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protocol ECOEMS
Description: Use electo estimulation therapy. The 4-channel stimulator will be used. The 6 electrodes will be located on the biceps, triceps and deltoids. Two daily sessions will be distributed, five days a week, lasting 20 minutes, the vascular program designed by the electro stimulation team itself will be applied.
Study: NCT06264960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy
Description: After the patient was admitted to the angiography laboratory, approximately 10 minutes before the angiography procedure commenced, they were seated and allowed to relax. Music was played using a digital MP3 player.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography. The exercises were performed in a single patient room, in a quiet and calm environment. During the first 5 minutes, the researcher explained how the exercise was done with pictures and showed it to the patient. The patient was then asked to do the exercise for 10 minutes under the supervision of the researcher.
Study: NCT04774705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )
Description: A transcutaneous stimulator of the atrial branch of the vagus nerve of the TENS eco Plus type (Schwa-medico) will be used. SNV stimulation will be applied in the concha of the left ear to the subcutaneous area of the atrial branch of the vagus nerve in the left ear (cymba conchae) for each patient, at an intensity of 2 mA, 30 minutes per day for 5 consecutive days, from the day of inclusion / randomization.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: For the control group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
Study: NCT05523986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D (2000IU/day) for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06161350

Intervention type: COMBINATION_PRODUCT
Intervention: Structured multi-disciplinary approach
Description: Since 2010, a structured multidisciplinary team was formed to evaluate the child medically, support its nutrition, teach, treat and educate the children and parents and guide them through the process to obtain a normal and independent feeding behavior. The multidisciplinary team must have special expertise regarding digestive and nutritional as well as sensory and oral motor problems in children requiring artificial nutrition. The team must at least consist of a pediatrician, a dietician with experience in artificial nutrition in children, a speech therapist and/or physical therapist and a psychologist or orthopedagogue. The team should also be able to rely on a nurse with experience in artificial nutrition, a social assistant and a secretary.
Study: NCT06070363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Description: Acupuncture Needle Insertion
Study: NCT05467202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLL1 CAR-T
Description: A single infusion of autologous CLL1 CAR-T cells administered intravenously
Study: NCT05232786

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT06015282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational aQIVc
Description: Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: licensed QIV1
Description: Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
Study: NCT05928741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload
Description: Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload
Description: Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.
Study: NCT06489418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dew Restore Barrier Repair Cream
Description: Wash the face with the gentle cleanser to remove dirt, and oil and pat dry with the towel\| tissue paper. Afterwards take the pea side amount of the test product you finger tips, apply it over the face by small dotes and massage it in circular motion until it absorbed.~Frequency: Twice a Day Route of Administration: Topical
Study: NCT04691661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib HCl 50 mg
Description: Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04700787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem
Description: sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
Study: NCT06185322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy program with upper cross syndrome specific exercises
Description: Ten physical therapy sessions consisting of electrotherapy and upper cross syndrome -specific exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program with conventional neck strengthening exercises
Description: Ten physical therapy sessions consisting of electrotherapy and conventional neck strenthening exercises
Study: NCT05664919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA58 Nasal Spray
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Study: NCT06328387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.

Intervention type: DRUG
Group type: OTHER
Intervention: Sacituzumab Govitecan
Description: Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
Study: NCT05593549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: Trehalose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
Study: NCT05537987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-723
Description: 3+3 dose escalation
Study: NCT06406153

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Laronidase
Description: Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: An antihistamine is administered one hour before the infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: An antihistamine is administered one hour before the infusion.
Study: NCT06015282

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: licensed QIV2
Description: Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
Study: NCT06268197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: The yoga intervention will consist of twice weekly, in-person, gentle Hatha yoga classes delivered by a certified yoga instructor. Each class will last 60-75 minutes and will include an introduction to the day's topic, an opening breathing/meditation practice, yoga postures, a closing breathing/meditation practice, and end with a savasana pose and intention setting for a home practice.
Study: NCT06420869

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: A postural evaluation will be conducted, including the measurement of the thoracic kyphosis angle and the assessment of sagittal head posture.A proprioception evaluation will be conducted, whereby the cervical region, trunk and ankle joint position sense and trunk and foot sensation will be evaluated for the purpose of assessing the proprioception of the spine.Turkish adaptation of the Kyphosis Specific Spine Appearance Questionnaire (KSAQ) will be employed to assess postural appearance perception. The KSAQ is a reliable and valid patient-reported outcome tool for assessing individual perception of various aspects of kyphotic deformity and appearance in young patients with kyphosis. KSAQ is a 10-item questionnaire based on a five-point Likert scale, with responses ranging from 1 to 5. The mean of the responses is used to obtain a total score for the KSAQ. The questionnaire is related to patients' perception of appearance, with higher scores indicating a worsening of the deformity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: A postural evaluation will be conducted, including the measurement of the thoracic kyphosis angle and the assessment of sagittal head posture.A proprioception evaluation will be conducted, whereby the cervical region, trunk and ankle joint position sense and trunk and foot sensation will be evaluated for the purpose of assessing the proprioception of the spine.Turkish adaptation of the Kyphosis Specific Spine Appearance Questionnaire (KSAQ) will be employed to assess postural appearance perception. The KSAQ is a reliable and valid patient-reported outcome tool for assessing individual perception of various aspects of kyphotic deformity and appearance in young patients with kyphosis. KSAQ is a 10-item questionnaire based on a five-point Likert scale, with responses ranging from 1 to 5. The mean of the responses is used to obtain a total score for the KSAQ. The questionnaire is related to patients' perception of appearance, with higher scores indicating a worsening of the deformity.
Study: NCT04596891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.
Study: NCT06098079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone-Bupropion (NB) Combination
Description: A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
Study: NCT06649149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genially
Description: In the study, an educational intervention will be prepared with the https://genially.com/ program, which is one of the interactive learning methods.
Study: NCT05917886

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auditory beat stimulation: 8Hz monaural beat stimulation
Description: Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auditory beat stimulation: 8Hz monaural beat stimulation
Description: Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
Study: NCT05809310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous intervention (stent) for PA stenosis
Description: Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries